Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.

Hayuka, Kotone; Okuyama, Hiroyuki; Murakami, Akitsu; Okita, Yoshihiro; Nishiuchi, Takamasa; Okano, Keiichi; Suzuki, Yasuyuki; Tsuji, Akihito

Hayuka, Kotone; Okuyama, Hiroyuki; Murakami, Akitsu; Okita, Yoshihiro; Nishiuchi, Takamasa; Okano, Keiichi; Suzuki, Yasuyuki; Tsuji, Akihito.

Affiliation

Hayuka K; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan, hayuka@med.kagawa-u.ac.jp.
Okuyama H; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Murakami A; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Okita Y; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Nishiuchi T; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Okano K; Department of Gastroenterological Surgery, Kagawa University, Takamatsu, Japan.
Suzuki Y; Department of Gastroenterological Surgery, Kagawa University, Takamatsu, Japan.
Tsuji A; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.

Chemotherapy ; 66(3): 58-64, 2021.

Article in En | MEDLINE | ID: mdl-34284397

Subject(s)
Key words

FOLFIRINOX; Gemcitabine; Nab-paclitaxel; Pancreatic cancer; Second-line treatment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Paclitaxel / Deoxycytidine / Albumins / Antineoplastic Agents Type of study: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Chemotherapy Year: 2021 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google